Press releases View full list

December 02, 2014

Invitae receives accreditation for its laboratory from the College of American Pathologists

SAN FRANCISCO, December 2, 2014 – Invitae Corporation, a genetic information company, announced that it has received accreditation from the College of American Pathologists (CAP). 

The CAP accreditation is awarded to facilities that meet the highest standards of quality in laboratory services. According to the Commission on Laboratory Accreditation, the U.S. government recognizes the CAP Laboratory Accreditation Program, which began in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program. 

During the CAP accreditation process, inspectors perform an on-site inspection and examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and records, as well as overall management. 

"Receiving CAP accreditation is an important recognition of our laboratory as we continue to advance our goal to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today," said Martin Powers, MD, lab director at Invitae. 

With this recognition, the Invitae laboratory joins the prestigious ranks of CAP-accredited facilities worldwide.

About Invitae

Based in San Francisco, Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic test comprising over 200 genes for a variety of genetic disorders associated primarily with cancer, but also covering cardiology, hematology, neurology and pediatrics. For further information, please visit www.invitae.com.

Contact:

Katherine Stueland

pr@invitae.com

415.254.1233

NYSE: NVTA 21.79 +0.11 +0.51% Volume: 1,308,192 20 minute delay September 16, 2019

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com